

SGLT2 Available

Adapted from Cardiac benefits in Diabetes Therapy: Comparing SGLT2 Inhibitors and GLP-1 Agonists

By Samuel Grossman, BS Pharm, PharmD, CDE, FADE

	Empagliflozin (Jardiance)	Canagliflozin (Invokana)	Dapagliflozin (Farxiga)	Ertugliflozin (Steglaro)
Dosing range	10-25mg daily	100-300mg daily	5-10mg daily	5-15mg daily
FDA label for CV benefit	Yes	Yes	No	No
eGFR limit	<45	100 mg if eGFR=45-60. <45 CI	<45 don't initiate. <30 CI	<30-60 don't initiate. <30 CI
Hepatic impairment	No dose adjustment	Severe impairment	No dose adjustment	Severe impairment

CV: cardiovascular

CI: contraindicated

eGFR: Estimated glomerular filtration rate

References:

- <https://www.invokanahcp.com/dosing>
- <https://www.farxiga-hcp.com/>
- <https://www.jardiance.com/>
- <https://www.ajmc.com/newsroom/new-sgl2-competitor-steglatro-approved-for-type-2-diabetes> access 9/19